Cantor Fitzgerald lifts Orchard Therapeutics plc [ORTX] price estimate. Who else is bullish?


Orchard Therapeutics plc [NASDAQ: ORTX] loss -2.52% or -0.03 points to close at $1.16 with a heavy trading volume of 9396028 shares. The company report on November 18, 2021 that Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome.

100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


It opened the trading session at $1.25, the shares rose to $1.45 and dropped to $1.16, the range by which the price of stock traded the whole day. The daily chart for ORTX points out that the company has recorded -73.58% loss over the past six months. However, it is still 0.0% lower than its most recent low trading price.

If we look at the average trading volume of 985.26K shares, ORTX reached to a volume of 9396028 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Orchard Therapeutics plc [ORTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ORTX shares is $10.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ORTX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Orchard Therapeutics plc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 29, 2021. The new note on the price target was released on November 16, 2021, representing the official price target for Orchard Therapeutics plc stock.

The Average True Range (ATR) for Orchard Therapeutics plc is set at 0.11, with the Price to Sales ratio for ORTX stock in the period of the last 12 months amounting to 119.49. The Price to Book ratio for the last quarter was 0.61, with the Price to Cash per share for the same quarter was set at 2.06.

Trading performance analysis for ORTX stock

Orchard Therapeutics plc [ORTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.08. With this latest performance, ORTX shares dropped by -14.71% in over the last four-week period, additionally sinking by -73.58% over the last 6 months – not to mention a drop of -73.93% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORTX stock in for the last two-week period is set at 31.90, with the RSI for the last a single of trading hit 30.58, and the three-weeks RSI is set at 32.27 for Orchard Therapeutics plc [ORTX]. The present Moving Average for the last 50 days of trading for this stock 1.5604, while it was recorded at 1.2480 for the last single week of trading, and 3.6390 for the last 200 days.

Orchard Therapeutics plc [ORTX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Orchard Therapeutics plc [ORTX] shares currently have an operating margin of -6863.51 and a Gross Margin at -10.25. Orchard Therapeutics plc’s Net Margin is presently recorded at -5856.61.

Return on Total Capital for ORTX is now -61.71, given the latest momentum, and Return on Invested Capital for the company is -54.50. Return on Equity for this stock declined to -64.13, with Return on Assets sitting at -45.03. When it comes to the capital structure of this company, Orchard Therapeutics plc [ORTX] has a Total Debt to Total Equity ratio set at 32.60. Additionally, ORTX Total Debt to Total Capital is recorded at 24.58, with Total Debt to Total Assets ending up at 20.70. Long-Term Debt to Equity for the company is recorded at 24.87, with the Long-Term Debt to Total Capital now at 18.75.

Reflecting on the efficiency of the workforce at the company, Orchard Therapeutics plc [ORTX] managed to generate an average of -$683,756 per employee. Receivables Turnover for the company is 0.15 with a Total Asset Turnover recorded at a value of 0.01.Orchard Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.50 and a Current Ratio set at 6.60.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Orchard Therapeutics plc [ORTX]

There are presently around $87 million, or 60.10% of ORTX stock, in the hands of institutional investors. The top three institutional holders of ORTX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 11,028,722, which is approximately -10.446% of the company’s market cap and around 0.12% of the total institutional ownership; ARTISAN PARTNERS LIMITED PARTNERSHIP, holding 10,846,420 shares of the stock with an approximate value of $12.91 million in ORTX stocks shares; and FMR LLC, currently with $10.25 million in ORTX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Orchard Therapeutics plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 39 institutional holders increased their position in Orchard Therapeutics plc [NASDAQ:ORTX] by around 7,088,238 shares. Additionally, 36 investors decreased positions by around 14,097,359 shares, while 18 investors held positions by with 51,621,322 shares. The mentioned changes placed institutional holdings at 72,806,919 shares, according to the latest SEC report filing. ORTX stock had 12 new institutional investments in for a total of 1,611,066 shares, while 15 institutional investors sold positions of 5,099,215 shares during the same period.